Progressive multiple sclerosis (MS) will be a major area of research interest for years to come. No treatments exist and success in the field will generalise to other neurological conditions where neurodegeneration coexists with neuroinflammation. The issue is complex, and interdisciplinary approaches – uniting scientists with different competences (neurobiology, immunogenetics, etc.) and ‘mindsets’ (academia and industry) – will be decisive. The International Progressive MS Alliance is catalysing this process through various initiatives, the most recent of which was a meeting where scientists from academia (also outside the MS field) and from industry reviewed data and strategies to determine the next steps towards the translation of current knowledge into effective therapies.
Key findings are:
(i). Concerted efforts are essential to prioritise pathogenetic mechanisms according to impact on the disease and druggability.
(ii). Combination therapies will probably be needed, possibly early in the disease, along with new trial designs and treatment schedules.
(iii). Drug screenings are a pragmatic approach hopefully enriched by the use of neural and oligodendrocyte progenitors differentiated from induced pluripotent stem cells (iPSCs).
(iv). The field of network biology will increase our ability to predict therapeutic targets.
(v). Genome-wide association studies (GWAS) must try to identify variants associated with disease progression.
ThompsonAJ. A much-needed focus on progression in multiple sclerosis. Lancet Neurol2015; 14: 133–135.
3.
FoxRJThompsonAJBakerD. Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS. Mult Scler2012; 18: 1534–1540.
4.
MagliozziRHowellOVoraA. Meningeal B-cell follicles in secondary progressive multiple sclerosis associated with early onset of disease and severe cortical pathology. Brain2007; 130: 1089–1104.
5.
Bar-OrAFawazLFanB. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?Ann Neurol2010; 67: 452–461.
6.
BarrTAShenPBrownS. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med2012; 209: 1001–1010.
7.
YoshizakiAMiyagakiTDiLilloDJ. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature2012; 491: 264–268.
8.
ShenPRochTLampropoulouV. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature2014; 507: 366–370.
9.
GuseoAJellingerK. The significance of perivascular infiltrations in multiple sclerosis. J Neurol1975; 211: 51–60.
10.
ChardDTGriffinCMRashidW. Progressive grey matter atrophy in clinically early relapsing–remitting multiple sclerosis. Mult Scler2004; 10: 387–391.
11.
KutzelniggALucchinettiCFStadelmanC. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain2005; 128: 2705–2712.
12.
FisherELeeJCNajamuraK. Gray matter atrophy in multiple sclerosis: A longitudinal study. Ann Neurol2008; 64: 255–265.
FilippiMvan der HeuvelMPFornitoA. Gray matter damage predicts the accumulation of disability 13 years later in MS. Neurology2013; 81: 1759–1767.
15.
MaineroCLouapreC. Meningeal inflammation in multiple sclerosis: The key to the origin of cortical lesions ?Neurology2015; 85: 12–13.
16.
GardnerCMagliozziRDurrenbergerPF. Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. Brain2013; 136: 3596–3608.
17.
SerafiniBRosicarelliBFranciottaD. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med2007; 204: 2899–2912.
18.
JaquiéryEJilekSSchluepM. Intrathecal immune responses to EBV in early MS. Eur J Immunol2010; 40: 878–887.
19.
AngeliniDFSerafiniBPirasE. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog2013; 9: e1003220.
20.
LossiusAJohansenJNVartdalF. High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells. Eur J Immunol2014; 44: 3439–3452.
21.
van NieropGPMautnerJMitterreiterJG. Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins. Mult Scler. Epub ahead of print 3June2015. pii: 1352458515588581.
22.
LouveauASmirnovIKeyesTJ. Structural and functional features of central nervous system lymphatic vessels. Nature2015; 532: 337–341.
23.
AspelundAAntilaSProulxST. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med2015; 212: 991–999.
24.
PrinzMPrillerJ. Microglia and brain macrophages in the molecular age: From origin to neuropsychiatric disease. Nat Rev Neurosci2014; 15: 300–312.
25.
GoldmannTWieghoferPMüllerPF. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat Neurosci2013; 16: 1618–1626.
26.
YeungMSZdunekSBergmannO. Dynamics of oligodendrocyte generation and myelination in the human brain. Cell2014; 159: 766–774.
27.
GalloVDeneenB. Glial development: The crossroads of regeneration and repair in the CNS. Neuron2014; 83: 283–308.
28.
MayoLTraugerSABlainM. Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nat Med2014; 20: 1147–1156.
29.
BrosnanCFRaineCS. The astrocyte in multiple sclerosis revisited. Glia2013; 61: 453–465.
30.
JunkerAKrumbholzMEiseleS. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain2009; 132: 3342–3352.
31.
AggarwalSYurlovaLSimonsM. Central nervous system myelin: Structure, synthesis and assembly. Trends Cell Biol2011; 21: 585–593.
32.
WheelerDBandaruVVCalabresiPA. A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain2008; 131: 3092–3102.
33.
WheelerDKnappEBandaruVV. Tumor necrosis factor-alpha-induced neural sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J Neurochem2009; 109: 1237–1249.
34.
KaulM. HIV’s double strike at the brain: Neuronal toxicity and compromised neurogenesis. Front Biosci2008; 13: 2484–2494.
CampbellGRZiabrevaIReeveAK. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol2011; 69: 481–492.
37.
StysPKZamponiGWvan MinnenJ. Will the real multiple sclerosis please stand up?Nat Rev Neurosci2012; 13: 507–514.
38.
StysPK. Pathoetiology of multiple sclerosis: Are we barking up the wrong tree?F1000Prime Rep2013; 5: 20.
39.
Di PardoAAmicoEFavellatoM. FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Hum Mol Genet2014; 23: 2251–2265.
40.
DeograciasRYazdaniMDekkersMP. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci U S A2012; 109: 14230–14235.
41.
DoiYTacheuchiHHoriuchiH. Fingolimod phosphate attenuates oligomeric amyloid beta-induced neurotoxicity via increased brain-derived neurotrophic factor expression in neurons. PLoS One2013; 8: e61988.
AnthonyDCSibsonNRLoseyP. Investigation of immune and CNS-mediate effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model. Neuropharmacology2014; 79: 534–541.
44.
BrückWPförtnerRPhamT. Reduced astrocytic NF-kB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol2012; 124: 411–424.
45.
HawkerKO’ConnorPFreedmanMS. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized, double-blind placebo-controlled multicenter trial. Ann Neurol2009; 66: 460–471.
46.
MiSPepinskiRBCadavidD. Blocking LINGO-1 as a therapy to promote CNS repair: From concept to the clinic. CNS Drugs2013; 27: 493–503.
47.
BennetDADe JagerPL. Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer’s disease. Biochem Pharmacol2014; 88: 617–630.
48.
CalifanoAButteAJFriendS. Leveraging models of cell regulation and GWAS data in integrative network-based association studies. Nat Genet2012; 44: 841–847.
49.
ChenJCAlvarezMJTalosF. Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. Cell2014; 159: 402–414.
50.
AubrySShinWCraryJF. Assembly and interrogation of Alzheimer’s disease genetic networks reveal novel regulators of progression. PLoS One2015; 10: e0120352.
51.
BrichtaLShinWJackson-LewisV. Satb1 orchestrates an intrinsic network against dopaminergic neuron degeneration. Nat Neurosci2015, in press.
52.
IkizBAlvarezMJRéDB. The regulatory machinery of neurodegeneration in in vitro models of amyotrophic lateral sclerosis. Cell Rep2015; 12: 335–345.
53.
WangLKhankhanianPBaranziniSE. iCTNet: A Cytoscape plugin to produce and analyze integrative complex traits networks. BMC Bioinformatics2011; 12: 380.
54.
DeshmukhVATardifVLyssiotisCA. A regenerative approach to the treatment of multiple sclerosis. Nature2013; 502: 327–332.
55.
MeiFFancySPShenYA. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med2014; 20: 954–960.
56.
NajmFJMadhavanMZarembaA. Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo. Nature2015; 522: 216–220.
57.
SobottkaBZieglerUKaechA. CNS live imaging reveals a new mechanism of myelination: The liquid croissant model. Glia2011; 59: 1841–1849.
58.
FoxIJDaleyGQGoldmanSA. Stem cells therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease. Science2014; 345: 1247391.
59.
LaterzaCMerliniADe FeoD. iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF. Nat Commun2013; 4: 2597.
60.
BakerDAmorS. Mouse models of multiple sclerosis: Lost in translation?Curr Pharm Des2015; 21: 2440–2452.
